Literature DB >> 10677346

Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.

I J Moon1, Y Lee, C S Kwak, J H Lee, K Choi, A D Schreiber, J G Park.   

Abstract

Systematic secondary structure simulation of a target mRNA sequence is shown to be effective for locating a good anti-sense target site. Multiple selected anti-sense sequences were placed in a single molecule. The anti-sense oligonucleotide (oligo) was covalently closed to avoid exonuclease activities and was designated CMAS (covalently closed multiple anti-sense)-oligo. CMAS-oligo was found to be stable, largely preserving its structural integrity after 24 h of incubation in the presence of either exonuclease III or serum. When human c-myb mRNA was targeted by the c-myb CMAS-oligo, expression of the gene was completely abolished. Further, tumour cell growth was inhibited by 82+/-3% as determined by an MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay and by 90+/-1% by [(3)H]thymidine incorporation. When a leukaemic cell line K562 was treated with CMAS-oligo, colony formation on soft agarose was also decreased by 93%. In contrast, treatment with a scrambled control oligo did not significantly inhibit leukaemic cell growth. These results suggest that a rational target site search is possible for an anti-sense oligo and that CMAS-oligo can be employed as an effective anti-sense agent with enhanced stability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677346      PMCID: PMC1220853     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.

Authors:  C Melani; L Rivoltini; G Parmiani; B Calabretta; M P Colombo
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

Review 2.  Antisense agents in cancer research and therapeutics.

Authors:  B J Dolnick
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

3.  RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds.

Authors:  P J Furdon; Z Dominski; R Kole
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

4.  Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells.

Authors:  M B Kastan; K D Stone; C I Civin
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

5.  An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines.

Authors:  G Anfossi; A M Gewirtz; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Biologic and therapeutic significance of MYB expression in human melanoma.

Authors:  N Hijiya; J Zhang; M Z Ratajczak; J A Kant; K DeRiel; M Herlyn; G Zon; A M Gewirtz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma.

Authors:  P S Eder; R J DeVine; J M Dagle; J A Walder
Journal:  Antisense Res Dev       Date:  1991

8.  Implication of RNA structure on antisense oligonucleotide hybridization kinetics.

Authors:  W F Lima; B P Monia; D J Ecker; S M Freier
Journal:  Biochemistry       Date:  1992-12-08       Impact factor: 3.162

9.  Effects of the antisense v-myb' expression on K562 human leukemia cell proliferation and differentiation.

Authors:  H Kamano; H Ohnishi; T Tanaka; K Ikeda; A Okabe; S Irino
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

10.  In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

Authors:  W B Offensperger; S Offensperger; E Walter; K Teubner; G Igloi; H E Blum; W Gerok
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  3 in total

1.  Effective inhibition of cancer cell growth by a novel tripartite transfection complex containing ribbon antisense molecules to hTR.

Authors:  Jong-Gu Park
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

2.  Identification of genes involved in liver cancer cell growth using an antisense library of phage genomic DNA.

Authors:  Yun Han Lee; Young Ho Kim; Jong Gu Park
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

3.  Effects of TGF-beta1 Ribbon Antisense on CCl(4)-induced Liver Fibrosis.

Authors:  Doh Kyung-Oh
Journal:  Korean J Physiol Pharmacol       Date:  2008-02-28       Impact factor: 2.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.